Logo image of ABSI

ABSCI CORP (ABSI) Stock Overview

USA - NASDAQ:ABSI - US00091E1091 - Common Stock

4.53 USD
-0.34 (-6.98%)
Last: 10/17/2025, 8:00:00 PM
4.6082 USD
+0.08 (+1.73%)
After Hours: 10/17/2025, 8:00:00 PM

ABSI Key Statistics, Chart & Performance

Key Statistics
Market Cap677.33M
Revenue(TTM)4.14M
Net Income(TTM)-113296000
Shares149.52M
Float135.37M
52 Week High6.33
52 Week Low2.01
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.94
PEN/A
Fwd PEN/A
Earnings (Next)11-05 2025-11-05/bmo
IPO2021-07-22
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


ABSI short term performance overview.The bars show the price performance of ABSI in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 20 40 60

ABSI long term performance overview.The bars show the price performance of ABSI in the last 1, 2 and 3 years. 1 year 2 years 3 years 50 100 150 200

The current stock price of ABSI is 4.53 USD. In the past month the price increased by 73.56%. In the past year, price increased by 7.6%.

ABSCI CORP / ABSI Daily stock chart

ABSI Latest News, Press Relases and Analysis

ABSI Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 21.68 405.55B
AMGN AMGEN INC 13.7 160.87B
GILD GILEAD SCIENCES INC 15.87 152.38B
VRTX VERTEX PHARMACEUTICALS INC 24.61 106.87B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 63.14B
REGN REGENERON PHARMACEUTICALS 12.67 61.27B
ARGX ARGENX SE - ADR 91.6 51.94B
INSM INSMED INC N/A 35.04B
ONC BEONE MEDICINES LTD-ADR 5.11 34.76B
BNTX BIONTECH SE-ADR N/A 25.28B
NTRA NATERA INC N/A 24.94B
BIIB BIOGEN INC 8.93 20.97B

About ABSI

Company Profile

ABSI logo image Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. The company is headquartered in Vancouver Washington, Washington and currently employs 156 full-time employees. The company went IPO on 2021-07-22. Its Integrated Drug Creation platform combines artificial intelligence (AI) models with a synthetic biology data engine, enabling the design of therapeutics that address challenging therapeutic targets. Its approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Alongside collaborations with pharmaceutical, biotech, tech, and academic companies, the Company is advancing its own pipeline of AI- designed therapeutics. These include ABS-101, an antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, for hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness. The company has four wholly owned, internally developed programs focusing on cytokine biology. Its other pipeline programs include ABS-301 and ABS-501.

Company Info

ABSCI CORP

18105 Se Mill Plain Blvd

Vancouver Washington WASHINGTON US

CEO: Sean McClain

Employees: 157

ABSI Company Website

ABSI Investor Relations

Phone: 13609491041

ABSCI CORP / ABSI FAQ

What is the stock price of ABSCI CORP today?

The current stock price of ABSI is 4.53 USD. The price decreased by -6.98% in the last trading session.


What is the ticker symbol for ABSCI CORP stock?

The exchange symbol of ABSCI CORP is ABSI and it is listed on the Nasdaq exchange.


On which exchange is ABSI stock listed?

ABSI stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ABSCI CORP stock?

14 analysts have analysed ABSI and the average price target is 8.29 USD. This implies a price increase of 82.99% is expected in the next year compared to the current price of 4.53. Check the ABSCI CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ABSCI CORP worth?

ABSCI CORP (ABSI) has a market capitalization of 677.33M USD. This makes ABSI a Small Cap stock.


How many employees does ABSCI CORP have?

ABSCI CORP (ABSI) currently has 157 employees.


What are the support and resistance levels for ABSCI CORP (ABSI) stock?

ABSCI CORP (ABSI) has a support level at 4.02 and a resistance level at 5.83. Check the full technical report for a detailed analysis of ABSI support and resistance levels.


Is ABSCI CORP (ABSI) expected to grow?

The Revenue of ABSCI CORP (ABSI) is expected to decline by -2.69% in the next year. Check the estimates tab for more information on the ABSI EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ABSCI CORP (ABSI) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ABSCI CORP (ABSI) stock pay dividends?

ABSI does not pay a dividend.


When does ABSCI CORP (ABSI) report earnings?

ABSCI CORP (ABSI) will report earnings on 2025-11-05, before the market open.


What is the Price/Earnings (PE) ratio of ABSCI CORP (ABSI)?

ABSCI CORP (ABSI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.94).


What is the Short Interest ratio of ABSCI CORP (ABSI) stock?

The outstanding short interest for ABSCI CORP (ABSI) is 24.47% of its float. Check the ownership tab for more information on the ABSI short interest.


ABSI Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to ABSI. When comparing the yearly performance of all stocks, ABSI is one of the better performing stocks in the market, outperforming 86.16% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ABSI Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ABSI. While ABSI seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ABSI Financial Highlights

Over the last trailing twelve months ABSI reported a non-GAAP Earnings per Share(EPS) of -0.94. The EPS decreased by -0.64% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -53.98%
ROE -65.35%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-9.09%
Sales Q2Q%-53.31%
EPS 1Y (TTM)-0.64%
Revenue 1Y (TTM)27.48%

ABSI Forecast & Estimates

14 analysts have analysed ABSI and the average price target is 8.29 USD. This implies a price increase of 82.99% is expected in the next year compared to the current price of 4.53.

For the next year, analysts expect an EPS growth of 6.99% and a revenue growth -2.69% for ABSI


Analysts
Analysts82.86
Price Target8.29 (83%)
EPS Next Y6.99%
Revenue Next Year-2.69%

ABSI Ownership

Ownership
Inst Owners60%
Ins Owners6.22%
Short Float %24.47%
Short Ratio6.21